YL252 / MediLink - LARVOL DELTA

YL252: A dual-functional PD-L1/VEGF-targeting ADC integrating immunotherapy, anti-angiogenesis, and cytotoxicity (AACR 2026) - "Repeat-dose toxicology studies established a favorable safety profile, with a therapeutic index of approximately 100 and no drug-related adverse findings in major organs, including lung, liver, and kidney. In summary, YL252 is the first reported ADC that concurrently blocks PD-L1, inhibits VEGF-driven angiogenesis, and releases a cytotoxic payload in the tumor microenvironment, representing a single-agent approach that integrates immunotherapy, anti-angiogenic therapy, and chemotherapy mechanisms."

ADC • Oncology • PD-L1